Sotos syndrome

Last updated
Sotos syndrome
Other namesCerebral gigantism or Sotos-Dodge syndrome
Cerebral Gigantism 4.jpg
Girl displaying characteristic facial features of Sotos syndrome
Specialty Medical genetics   OOjs UI icon edit-ltr-progressive.svg

Sotos syndrome is a rare genetic disorder characterized by excessive physical growth during the first years of life. Excessive growth often starts in infancy and continues into the early teen years. The disorder may be accompanied by autism, [1] mild intellectual disability, delayed motor, cognitive, and social development, hypotonia (low muscle tone), and speech impairments. Children with Sotos syndrome tend to be large at birth and are often taller, heavier, and have relatively large skulls (macrocephaly) than is normal for their age. Signs of the disorder, which vary among individuals, include a disproportionately large skull with a slightly protrusive forehead, large hands and feet, large mandible, hypertelorism (an abnormally increased distance between the eyes), and downslanting eyes. Clumsiness, an awkward gait, and unusual aggressiveness or irritability may also occur.

Contents

Although most cases of Sotos syndrome occur sporadically, familial cases have also been reported. It is similar to Weaver syndrome.

Signs and symptoms

A child with Sotos syndrome showing characteristic facial features Sotos syndrome extracted.png
A child with Sotos syndrome showing characteristic facial features
Sotos syndrome in the hand, showing enlargement Cerebral Gigantism 3.jpg
Sotos syndrome in the hand, showing enlargement

This syndrome is characterized by overgrowth and advanced bone age. Affected individuals have dysmorphic features, with macrodolichocephaly, downslanting palpebral fissures and a pointed chin. The facial appearance is most notable in early childhood. Affected infants and children tend to grow quickly; they are significantly taller than their siblings and peers, and have an unusually large skull and large head. Adult height is usually in the normal range, although Broc Brown has the condition and was named the world's tallest teenager; as of late 2016, he was 2.34 m (7 ft 8 in) tall and still growing. [2]

Individuals with Sotos syndrome often have intellectual impairment, [3] [4] and most also display autistic traits. [5] Frequent behavioral impairments include attention deficit hyperactivity disorder (ADHD), phobias, obsessive compulsive disorder, tantrums, and impulsive behaviors (impulse control disorder). Problems with speech and language are also common. [6] Affected individuals may often have stuttering, difficulty with sound production, or a monotone voice. Additionally, weak muscle tone (hypotonia) may delay other aspects of early development, particularly motor skills such as sitting and crawling.[ citation needed ]

Other signs include scoliosis, seizures, heart or kidney defects, hearing loss, and problems with vision. Some infants with this disorder experience jaundice and poor feeding. A small number of patients with Sotos syndrome have developed cancer, most often in childhood, but no single form of cancer has been associated with this condition. It remains uncertain whether Sotos syndrome increases the risk of specific types of cancer. If persons with this disorder have any increased cancer risk, their risk is only slightly greater than that of the general population. [7]

Genetics

Autosomal dominant inheritance Autosomal dominant - en.svg
Autosomal dominant inheritance

Loss of function mutations in the NSD1 gene lead to the development of Sotos syndrome. [8] [9] The NSD1 gene provides instructions for making a protein (histone-lysine N-methyltransferase) that is expressed mainly in the brain, kidney, muscle, spleen, thymus, and lung. [10] In Sotos syndrome, a mutation in the NSD1 gene prevents the production of this protein. The specific function of this protein is not yet known but studies show that it is involved in histone modification, which affects transcription of other genes. [10] It is unclear how a reduced amount of this protein during development leads to learning disabilities, overgrowth, and the other features of Sotos syndrome. [10]

Mutations leading to Sotos syndrome can be sporadic or inherited in an autosomal dominant pattern. [10] About 95 percent of Sotos syndrome cases occur by spontaneous mutation involving the NSD1 gene. [10] 5 percent of individuals with Sotos syndrome have one affected parent. [10] In the Japanese population, the most common genetic change leading to Sotos syndrome is a microdeletion in the region of chromosome 5 containing the NSD1 gene (5q35 microdeletion). [11] In Japan, this microdeletion comprises over 50 percent of cases compared to only 10 percent worldwide. [11] In other populations, such as in Europe and the USA, small mutations called intragenic mutations within the NSD1 gene cause a majority of Sotos cases. [11] Individuals with a 5q35 microdeletion in the NSD1 gene have less overgrowth symptoms and more severe learning disability than those with an intragenic mutation. [10] 7 to 35 percent of Sotos patients have no NSD1 anomalies [11] .

Diagnosis

Diagnosis of Sotos syndrome is usually made during childhood and is based on clinical examination and bone age. [11] The clinical evaluation begins with a physician conducting a thorough history and physical examination, focusing on signs of excessive growth along with other previously mentioned symptoms. Family history is particularly important to identify any affected family members and provide genetic counseling if necessary. [12] Physicians will also perform an assessment of growth velocity with growth charts and head circumference measurements. [12] Bone age is determined by obtaining an X-ray. Additional diagnostic tests may be performed to rule out other disorders. This includes a complete blood count, karyotype analysis, and measurement of IGF-1, IGFBP-3, free T4, and TSH levels. [12] There are no biochemical markers for Sotos syndrome. [13] The diagnosis is confirmed through genetic testing. Physicians will obtain a blood or saliva sample for genetic testing which looks for a deletion within the NSD1 gene or a heterozygous pathogenic variant of the gene. [10] If there is clinical suspicion of Sotos syndrome in a fetus, physicians may perform genetic testing on the fetus. [14]

Treatment

Treatment is symptomatic. [13] There is no standard course of treatment for Sotos syndrome.[ citation needed ]

Prognosis

Sotos syndrome is not a life-threatening disorder and patients may have a normal life expectancy. Developmental delays may improve in the school-age years; however, coordination problems may persist into adulthood, along with any learning disabilities and/or other physical or mental issues. [15]

Epidemiology

Incidence is approximately 1 in 14,000 births. [6]

See also

Related Research Articles

<span class="mw-page-title-main">Fragile X syndrome</span> X-linked dominant genetic disorder

Fragile X syndrome (FXS) is a genetic neurodevelopmental disorder characterized by mild-to-moderate intellectual disability. The average IQ in males with FXS is under 55, while about two thirds of affected females are intellectually disabled. Physical features may include a long and narrow face, large ears, flexible fingers, and large testicles. About a third of those affected have features of autism such as problems with social interactions and delayed speech. Hyperactivity is common, and seizures occur in about 10%. Males are usually more affected than females.

<span class="mw-page-title-main">Megalencephaly</span> Medical condition

Megalencephaly is a growth development disorder in which the brain is abnormally large. It is characterized by a brain with an average weight that is 2.5 standard deviations above the mean of the general population. Approximately 1 out of 50 children (2%) are said to have the characteristics of megalencephaly in the general population.

<span class="mw-page-title-main">Macrocephaly</span> Abnormally large head size

Macrocephaly is a condition in which circumference of the human head is abnormally large. It may be pathological or harmless, and can be a familial genetic characteristic. People diagnosed with macrocephaly will receive further medical tests to determine whether the syndrome is accompanied by particular disorders. Those with benign or familial macrocephaly are considered to have megalencephaly.

<span class="mw-page-title-main">Rubinstein–Taybi syndrome</span> Rare genetic condition

Rubinstein–Taybi syndrome (RTS) is a rare genetic condition characterized by short stature, moderate to severe learning difficulties, distinctive facial features, and broad thumbs and first toes. Other features of the disorder vary among affected individuals. These characteristics are caused by a mutation or deletion in the CREBBP gene, located on chromosome 16, and/or the EP300 gene, located on chromosome 22.

<span class="mw-page-title-main">Neurofibromatosis type I</span> Type of neurofibromatosis disease

Neurofibromatosis type I (NF-1), or von Recklinghausen syndrome, is a complex multi-system human disorder caused by the mutation of neurofibromin 1 (NF-1). NF-1 is a gene on chromosome 17 that is responsible for production of a protein (neurofibromin) which is needed for normal function in many human cell types. NF-1 causes tumors along the nervous system that can grow anywhere on the body. NF-1 is one of the most common genetic disorders and is not limited to any person's race or sex. NF-1 is an autosomal dominant disorder, which means that mutation or deletion of one copy of the NF-1 gene is sufficient for the development of NF-1, although presentation varies widely and is often different even between relatives affected by NF-1.

Smith–Magenis syndrome (SMS), also known as 17p-microdeletion syndrome, is a microdeletion syndrome characterized by an abnormality in the short (p) arm of chromosome 17. It has features including intellectual disability, facial abnormalities, difficulty sleeping, and numerous behavioral problems such as self-harm. Smith–Magenis syndrome affects an estimated between 1 in 15,000 to 1 in 25,000 individuals.

<span class="mw-page-title-main">Heritability of autism</span> The rate at which autism is inherited

Autism has multiple causes. This article focuses on heritable causes. The heritability of autism is the proportion of differences in expression of autism that can be explained by genetic variation; if the heritability of a condition is high, then the condition is considered to be primarily genetic. Autism has a strong genetic basis. Although the genetics of autism are complex, autism spectrum disorder (ASD) is explained more by multigene effects than by rare mutations with large effects.

<span class="mw-page-title-main">Simpson–Golabi–Behmel syndrome</span> Congenital disorder

Simpson–Golabi–Behmel syndrome (SGBS) is a rare inherited congenital disorder that can cause craniofacial, skeletal, vascular, cardiac, and renal abnormalities. There is a high prevalence of cancer associated in those with SGBS which includes wilms tumors, neuroblastoma, tumors of the adrenal gland, liver, lungs and abdominal organs. The syndrome is inherited in an X-linked recessive manner. Females that possess one copy of the mutation are considered to be carriers of the syndrome but may still express varying degrees of the phenotype, suffering mild to severe malady. Males experience a higher likelihood of fetal death.

<span class="mw-page-title-main">22q13 deletion syndrome</span> Rare genetic syndrome

22q13 deletion syndrome, known as Phelan–McDermid syndrome (PMS), is a genetic disorder caused by deletions or rearrangements on the q terminal end of chromosome 22. Any abnormal genetic variation in the q13 region that presents with significant manifestations (phenotype) typical of a terminal deletion may be diagnosed as 22q13 deletion syndrome. There is disagreement among researchers as to the exact definition of 22q13 deletion syndrome. The Developmental Synaptopathies Consortium defines PMS as being caused by SHANK3 mutations, a definition that appears to exclude terminal deletions. The requirement to include SHANK3 in the definition is supported by many but not by those who first described 22q13 deletion syndrome.

<span class="mw-page-title-main">Muenke syndrome</span> Medical condition

Muenke syndrome, also known as FGFR3-related craniosynostosis, is a human specific condition characterized by the premature closure of certain bones of the skull during development, which affects the shape of the head and face. First described by Maximilian Muenke, the syndrome occurs in about 1 in 30,000 newborns. This condition accounts for an estimated 8 percent of all cases of craniosynostosis.

Weaver syndrome is an extremely rare autosomal dominant genetic disorder associated with rapid growth beginning in the prenatal period and continuing through the toddler and youth years. It is characterized by advanced osseous maturation and distinctive craniofacial, skeletal and neurological abnormalities. It is similar to Sotos syndrome and is classified as an overgrowth syndrome.

<span class="mw-page-title-main">NSD1</span> Mammalian protein found in Homo sapiens

NSD1 is a transcription coregulator protein that encodes Histone Methyltransferase and is associated with Sotos syndrome and Weaver syndrome.

<span class="mw-page-title-main">2p15-16.1 microdeletion syndrome</span> Medical condition

2p15-16.1 microdeletion is an extremely rare genetic disorder caused by a small deletion in the short arm of human chromosome 2. First described in two patients in 2007, by 2013 only 21 people have been reported as having the disorder in the medical literature.

<span class="mw-page-title-main">Koolen–De Vries syndrome</span> Rare genetic disorder caused by a deletion of six genes

Koolen–De Vries syndrome (KdVS), also known as 17q21.31 microdeletion syndrome, is a rare genetic disorder caused by a deletion of a segment of chromosome 17 which contains six genes. This deletion syndrome was discovered independently in 2006 by three different research groups.

1q21.1 deletion syndrome is a rare aberration of chromosome 1. A human cell has one pair of identical chromosomes on chromosome 1. With the 1q21.1 deletion syndrome, one chromosome of the pair is not complete, because a part of the sequence of the chromosome is missing. One chromosome has the normal length and the other is too short.

<span class="mw-page-title-main">17q12 microdeletion syndrome</span> Rare genetic anomaly in humans

17q12 microdeletion syndrome, also known as 17q12 deletion syndrome, is a rare chromosomal anomaly caused by the deletion of a small amount of material from a region in the long arm of chromosome 17. It is typified by deletion of the HNF1B gene, resulting in kidney abnormalities and renal cysts and diabetes syndrome. It also has neurocognitive effects, and has been implicated as a genetic factor for autism and schizophrenia.

<span class="mw-page-title-main">DiGeorge syndrome</span> Medical condition caused by chromosomal abnormality

DiGeorge syndrome, also known as 22q11.2 deletion syndrome, is a syndrome caused by a microdeletion on the long arm of chromosome 22. While the symptoms can vary, they often include congenital heart problems, specific facial features, frequent infections, developmental disability, intellectual disability and cleft palate. Associated conditions include kidney problems, schizophrenia, hearing loss and autoimmune disorders such as rheumatoid arthritis or Graves' disease.

16p11.2 deletion syndrome is a rare genetic condition caused by microdeletion on the short arm of chromosome 16. Most affected individuals experience global developmental delay and intellectual disability, as well as childhood-onset obesity. 16p11.2 deletion is estimated to account for approximately 1% of autism spectrum disorder cases.

Tatton-Brown–Rahman syndrome (TBRS) is a rare overgrowth and intellectual disability syndrome caused by autosomal dominant mutations in the DNMT3A gene. The syndrome was first recognized in 2014 by Katrina Tatton-Brown, Nazneen Rahman, and collaborators.

Malan syndrome (MALNS) is a rare overgrowth syndrome caused by autosomal dominant mutations in the NFIX gene. The syndrome is characterized by overgrowth, craniofacial dysmorphia, intellectual disability, and behavioral issues. It was formerly diagnosed as Sotos syndrome 2.

References

  1. ↑ "Exploring Autism". www.exploringautism.org. Archived from the original on 2002-08-11.
  2. ↑ "7-foot-tall Broc Brown: Facts". Morning News USA. Retrieved 8 March 2017.
  3. ↑ Lane C, Milne E, Freeth M (2016). "Cognition and Behaviour in Sotos Syndrome: A Systematic Review". PLOS ONE. 11 (2): e0149189. Bibcode:2016PLoSO..1149189L. doi: 10.1371/journal.pone.0149189 . PMC   4752321 . PMID   26872390.
  4. ↑ Lane C, Milne E, Freeth M (January 2018). "The cognitive profile of Sotos syndrome" (PDF). J Neuropsychol. 13 (2): 240–252. doi:10.1111/jnp.12146. PMID   29336120.
  5. ↑ Lane C, Milne E, Freeth M (January 2017). "Characteristics of Autism Spectrum Disorder in Sotos Syndrome". J Autism Dev Disord. 47 (1): 135–143. doi:10.1007/s10803-016-2941-z. PMC   5222916 . PMID   27771801.
  6. 1 2 Lane C, Van Herwegen J, Freeth M (December 2018). "Parent-Reported Communication Abilities of Children with Sotos Syndrome: Evidence from the Children's Communication Checklist-2". J Autism Dev Disord. 49 (4): 1475–1483. doi:10.1007/s10803-018-3842-0. PMC   6450847 . PMID   30536215.
  7. ↑ Reference, Genetics Home. "Sotos syndrome". Genetics Home Reference.
  8. ↑ Kurotaki N, Imaizumi K, Harada N, Masuno M, Kondoh T, Nagai T, et al. (April 2002). "Haploinsufficiency of NSD1 causes Sotos syndrome". Nat. Genet. 30 (4): 365–6. doi:10.1038/ng863. PMID   11896389. S2CID   205357840.
  9. ↑ Melchior L, Schwartz M, Duno M (March 2005). "dHPLC screening of the NSD1 gene identifies nine novel mutations--summary of the first 100 Sotos syndrome mutations". Ann. Hum. Genet. 69 (Pt 2): 222–6. doi:10.1046/j.1529-8817.2004.00150.x (inactive 8 January 2025). PMID   15720303.{{cite journal}}: CS1 maint: DOI inactive as of January 2025 (link)
  10. 1 2 3 4 5 6 7 8 Tatton-Brown, Katrina; Cole, Trevor RP; Rahman, Nazneen (1993), Adam, Margaret P.; Feldman, Jerry; Mirzaa, Ghayda M.; Pagon, Roberta A. (eds.), "Sotos Syndrome", GeneReviews®, Seattle (WA): University of Washington, Seattle, PMID   20301652 , retrieved 2025-01-07
  11. 1 2 3 4 5 Baujat, Geneviève; Cormier-Daire, Valérie (2007-09-07). "Sotos syndrome". Orphanet Journal of Rare Diseases. 2: 36. doi: 10.1186/1750-1172-2-36 . ISSN   1750-1172. PMC   2018686 . PMID   17825104.
  12. 1 2 3 Manor, Joshua; Lalani, Seema R. (2020). "Overgrowth Syndromes-Evaluation, Diagnosis, and Management". Frontiers in Pediatrics. 8: 574857. doi: 10.3389/fped.2020.574857 . ISSN   2296-2360. PMC   7661798 . PMID   33194904.
  13. 1 2 "Sotos Syndrome". NORD (National Organization for Rare Disorders). Retrieved 2016-03-01.
  14. ↑ Chen, Chih-Ping (June 2012). "Prenatal findings and the genetic diagnosis of fetal overgrowth disorders: Simpson-Golabi-Behmel syndrome, Sotos syndrome, and Beckwith-Wiedemann syndrome". Taiwanese Journal of Obstetrics & Gynecology. 51 (2): 186–191. doi:10.1016/j.tjog.2012.04.004. ISSN   1875-6263. PMID   22795092.
  15. ↑ Foster, Alison; Zachariou, Anna; Loveday, Chey; Ashraf, Tazeen; Blair, Edward; Clayton-Smith, Jill; Dorkins, Huw; Fryer, Alan; Gener, Blanca; Goudie, David; Henderson, Alex (2019). "The phenotype of Sotos syndrome in adulthood: A review of 44 individuals". Am J Med Genet C Semin Med Genet. 181 (4): 502–508. doi:10.1002/ajmg.c.31738. hdl: 11343/286377 . PMID   31479583. S2CID   201832354.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.